CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 40 enrolled
Drug / intervention
Furosemide Injection Solution (SCP-101) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02579057
NCT02579057Phase 3Completed
CompareCT.gov

Prospective, Randomized, Parallel-Group Pilot Study Comparing IV Furosemide to Subcutaneous Furosemide in Acute Decompensated Heart Failure Patients

Johns Hopkins University·interventional·Posted Oct 19, 2015·Updated Dec 18, 2017

In Brief

A Phase 3 clinical trial evaluating Furosemide Injection Solution (SCP-101) and Furosemide Injection Solution, USP for Congestive Heart Failure. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This study evaluates the clinical efficacy of subcutaneously administered Furosemide Injection Solution versus intravenous administration of Furosemide Injection, United States Pharmacopeia (USP) in adult patients presenting to a heart failure clinic with decompensated heart failure. Half of the patients will receive a subcutaneously administered Furosemide Injection Solution; the other half will receive an intravenous administration of Furosemide Injection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCongestive Heart Failure
CountriesUnited States
CollaboratorsscPharmaceuticals, Inc.

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 19, 2015
Enrollment StartFeb 1, 2016
Primary CompletionJun 1, 2017
Study CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.7 years ago

Interventions

Furosemide Injection Solution (SCP-101)drug

Furosemide Injection Solution, USPdrug